Campbell & Co Investment Adviser’s Prestige Consumer Healthcare PBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$906K Buy
+19,175
New +$985K 0.05% 577
2025
Q4
Sell
-7,238
Closed -$452K 1341
2025
Q3
$452K Buy
7,238
+423
+6% +$29.4K 0.03% 776
2025
Q2
$544K Sell
6,815
-14,804
-68% -$1.24M 0.03% 757
2025
Q1
$1.86M Buy
21,619
+6,054
+39% +$497K 0.14% 219
2024
Q4
$1.22M Buy
+15,565
New +$1.21M 0.09% 323
2022
Q2
Sell
-3,939
Closed -$209K 863
2022
Q1
$209K Buy
+3,939
New +$227K 0.06% 617
2017
Q3
Sell
-7,692
Closed -$406K 428
2017
Q2
$406K Buy
+7,692
New +$412K 0.38% 76
2013
Q4
Sell
-103,008
Closed -$3.1M 286
2013
Q3
$3.1M Buy
+103,008
New +$3.37M 0.61% 58

Other funds holding PBH

Campbell & Co Investment Adviser's PBH Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in Prestige Consumer Healthcare (PBH) in Q2 2026: 19,175 shares worth $906K. The stake represents 0.05% of the portfolio and ranks #577 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in PBH as recently as Q3 2025.

Campbell & Co Investment Adviser first reported a position in PBH in Q3 2013 and has held it in 8 quarters since. The position peaked at $3.1M in Q3 2013. 319 funds tracked by Wall St. Rank hold PBH as of Q2 2026.

  • Campbell & Co Investment Adviser held 19,175 shares of Prestige Consumer Healthcare worth $906K as of Q2 2026.
  • Prestige Consumer Healthcare was a new Campbell & Co Investment Adviser position in Q2 2026.
  • Prestige Consumer Healthcare made up 0.05% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #577 holding.
  • Campbell & Co Investment Adviser first reported a position in Prestige Consumer Healthcare in Q3 2013 and has held it in 8 quarters since.
  • Campbell & Co Investment Adviser's Prestige Consumer Healthcare position peaked at $3.1M in Q3 2013.
  • 319 funds tracked by Wall St. Rank held Prestige Consumer Healthcare as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.